Elevance Health, Inc. (FRA:A58)
Germany · Delayed Price · Currency is EUR | Market Cap | 72.85B -11.4% |
| Revenue (ttm) | 173.82B +9.4% |
| Net Income | 4.55B -11.4% |
| EPS | 20.40 -8.1% |
| Shares Out | n/a |
| PE Ratio | 16.02 |
| Forward PE | 15.16 |
| Dividend | 5.91 (1.77%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | n/a |
| Average Volume | 6 |
| Open | 340.60 |
| Previous Close | 334.50 |
| Day's Range | 340.60 - 340.60 |
| 52-Week Range | 235.80 - 375.40 |
| Beta | n/a |
| RSI | 77.63 |
| Earnings Date | Apr 22, 2026 |
About Elevance Health
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial numbers in USD Financial StatementsNews
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Elevance Health Transcript: AGM 2026
The meeting covered strong financial growth, board updates, and strategic initiatives in efficiency, digital transformation, and value-based care. All board proposals passed, while a shareholder proposal on political contributions failed.
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care
INDIANAPOLIS--(BUSINESS WIRE)--Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on ...
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider ...
Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
INDIANAPOLIS--(BUSINESS WIRE)--As small businesses continue to face rising healthcare costs, Elevance Health's affiliated health plans are delivering solutions that help employers offer competitive be...
Elevance Health upgraded at BofA on Medicaid margins trough
As previously reported, BofA analyst Kevin Fischbeck upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $405, citing increased confidence that Medicaid margins…
Elevance Health upgraded to Buy from Neutral at BofA
BofA analyst Kevin Fischbeck upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $425.
Elevance Health upgraded to Buy from Neutral at BofA
BofA upgraded Elevance Health (ELV) to Buy from Neutral with a price target of $435, up from $405.
Elevance Health price target raised to $411 from $397 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Elevance Health (ELV) to $411 from $397 and keeps an Overweight rating on the shares. The firm updated the company’s…
Elevance Health price target raised to $399 from $396 at Guggenheim
Guggenheim raised the firm’s price target on Elevance Health (ELV) to $399 from $396 and keeps a Buy rating on the shares. Q1 upside was “largely telegraphed, but nonetheless a…
Elevance Health price target raised to $408 from $393 at Barclays
Barclays raised the firm’s price target on Elevance Health (ELV) to $408 from $393 and keeps an Overweight rating on the shares post the Q1 report. The firm sys its…
Elevance Health price target raised to $364 from $357 at Leerink
Leerink raised the firm’s price target on Elevance Health (ELV) to $364 from $357 and keeps a Market Perform rating on the shares. Following Q1 results, the firm’s 2026 adjusted…
Elevance Health price target raised to $331 from $317 at Baird
Baird raised the firm’s price target on Elevance Health (ELV) to $331 from $317 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results…
Elevance Health Earnings Call Transcript: Q1 2026
Q1 results exceeded expectations with strong EPS and revenue growth, driven by ACA seasonality, cost management, and non-recurring investment income. Full-year EPS guidance was raised, and strategic investments in AI and Carelon are supporting operational improvements and long-term growth.
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health Wednesday reported nearly $1.8 billion in first quarter net income as costs continued to be a drag on earnings of the nation's second-largest health insurance company.
Elevance Health reports Q1 adjusted EPS $12.58, consensus $10.81
Reports Q1 revenue $49.5B, consensus $47.98B. “Our first quarter results exceeded expectations, reflecting underlying business strength and improving claims experience. We are raising our full-year ad...
Elevance Health raises FY26 adjusted EPS view to ‘at least $26.75’
Prior view was ‘at least’ $25.50, consensus $25.75.
Elevance raises annual profit forecast betting on cost control
Elevance Health raised its annual profit forecast on Wednesday, as it looks to keep medical costs in check.
Elevance Health backs FY26 operating cash flow view ‘at least $5.5B’
Guidance inclusive of potential cash payments for the CMS matter.
Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported first quarter 2026 results ahead of expectations. "Our first quarter results exceeded expectations, reflecting underlying busi...
Elevance Health price target lowered to $391 from $395 at Jefferies
Jefferies analyst David Windley lowered the firm’s price target on Elevance Health (ELV) to $391 from $395 and keeps a Buy rating on the shares. The firm adjusted estimates among…
Elevance Health price target lowered to $375 from $390 at Truist
Truist lowered the firm’s price target on Elevance Health (ELV) to $375 from $390 and keeps a Buy rating on the shares as part of a broader research note previewing…
Elevance Health initiated with an In Line at Evercore ISI
Evercore ISI analyst Elizabeth Anderson initiated coverage of Elevance Health (ELV) with an In Line rating and $345 price target Elevance is a diversified managed care company with “resilient” earning...